Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas.

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...